Literature DB >> 12922081

Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.

Jann Storsaeter1, Hans O Hallander, Lennart Gustafsson, Patrick Olin.   

Abstract

Prospectively collected data in a Swedish vaccine efficacy trial were used to investigate transmission of pertussis from small study infants to other household members. Forty one percent (258/627) of the exposed persons with paired serology had laboratory confirmed pertussis. The majority of those with laboratory confirmed pertussis had less than 14 days of cough and many were asymptomatic. High susceptibility to symptomatic pertussis was found among persons with low initial IgG antibody concentrations against pertussis toxin, especially those without previous history of pertussis vaccination or disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922081     DOI: 10.1016/s0264-410x(03)00407-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

Review 1.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

2.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.

Authors:  Girish S Kirimanjeswara; Luis M Agosto; Mary J Kennett; Ottar N Bjornstad; Eric T Harvill
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

3.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

4.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

5.  Decline of IgG pertussis toxin measured in umbilical cord blood, and neonatal and early infant serum.

Authors:  L C S Smallenburg; N A van Welie; L H Elvers; J C M van Huisseling; P F M Teunis; F G A Versteegh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-23       Impact factor: 3.267

Review 6.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

7.  Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.

Authors:  Maja Jahnmatz; Margaretha Ljungman; Eva Netterlid; Maria C Jenmalm; Lennart Nilsson; Rigmor Thorstensson
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

8.  Toward a new vaccine for pertussis.

Authors:  John B Robbins; Rachel Schneerson; Joanna Kubler-Kielb; Jerry M Keith; Birger Trollfors; Evgeny Vinogradov; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-20       Impact factor: 11.205

Review 9.  Resolving pertussis immunity and vaccine effectiveness using incidence time series.

Authors:  Jennie S Lavine; Pejman Rohani
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

10.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.